Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LMNL - Liminal Biosciences Inc


Close
8.5
0.010   0.118%

Share volume: 0
Last Updated: Mon 25 Sep 2023 10:00:00 PM CEST
Biological Product (except Diagnostic) Manufacturing : -3.41%

PREVIOUS CLOSE
CHG
CHG%

$8.49
0.01
0.12%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
21%
Profitability 18%
Dept financing 25%
Liquidity 48%
Performance 17%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$8.50
P/E Ratio 
0.00
DAY RANGE
N/A - $8.50
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
3.104 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Kenneth Galbraith
Region: US
Website: https://prometic.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

liminal biosciences inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. it operates through two segments, small molecule therapeutics and plasma derived therapeutics. the small molecule therapeutics segment's lead product candidate is fezagepras (pbi-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and alstrã¶m syndrome. the plasma derived therapeutics segment provides plasma protein purification system, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. it also engages in developing ryplazim for the treatment of congenital plasminogen deficiency. the company operates in canada, the united kingdom, and the united states. the company was formerly known as prometic life sciences inc. and changed its name to liminal biosciences inc. in october

Recent news